S&P 500
7,582.20
+0.03%
Dow Jones
51,018.80
+0.58%
Nasdaq 100
30,344.40
+0.25%
Russell 2000
2,916.31
-0.54%
FTSE 100
10,378.60
-0.32%
Nikkei 225
66,231.90
+0.67%

Health and Healthcare

Best BioHealth Stocks of 2010, Outlook for 2011 (JAZZ, DNDN, HGSI, ARIA, AMRN, NBIX, THRX)

Photo of Jon C. Ogg
By Jon C. Ogg Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Invalid Image
2010 has been an interesting year in biotech and in biohealth stocks, even if it has lacked some of the ten-baggers that were seen in 2009.  In 2009, companies like Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ), Dendreon Corp. (NASDAQ: DNDN), and Human Genome Sciences, Inc. (NASDAQ: HGSI) led the 2009 pack with exponential returns that were 500% and higher.  At BioHealthInvestor.com, we have tracked many of the exponential winners for 2010 with outlooks into 2011.  Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) is our sole repeat performer in 2010.  Others include ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Amarin Corporation plc (NASDAQ: AMRN), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Theravance Inc. (NASDAQ: THRX).

Many companies were screened out because performance has faltered or because of limited history.  Read the full lists below at BioHealthInvestor.com:

 

Stocks covered above in detail at BioHealthInvestor.com are ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), EntreMed Inc. (NASDAQ: ENMD), Exact Sciences Corporation (NASDAQ: EXAS), Exelixis, Inc. (NASDAQ: EXEL), Amicus Therapeutics, Inc. (NASDAQ: FOLD), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Amarin Corporation plc (NASDAQ: AMRN), Illumina Inc. (NASDAQ: ILMN), Inhibitex Inc. (NASDAQ: INHX), Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ), Neurocrine Biosciences Inc. (NASDAQ: NBIX), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Theravance Inc. (NASDAQ: THRX), and ViroPharma Inc. (NASDAQ: VPHM).

You can also see the same sort of search from 2009 for the 2010 outlook that was done at BioHealthInvestor.com.

JON C. OGG

Follow 24/7 Wall St. on Google
Photo of Jon C. Ogg
About the Author Jon C. Ogg →

Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. www.247wallst.com.

Continue Reading

Jon C. Ogg |

Nine Big Expected Biotech Winners for 2013 (ARIA, CBST, INCY, JAZZ, MDVN, ONXX, THRX, VPHM, VVUS)

Thinkstock24/7 Wall St. is looking for the next great biotech stocks for 2013 after great gains have been seen in…

Jon C. Ogg |

Top Biotech Stock Picks For 2012 (ARIA, DNDN, GILD, HGSI, ILMN, INCY, JAZZ, LIFE, THRX, IBB, XBI)

The biotech sector has seen its share of ups and downs in 2011 and prior years.  It is almost always…

Jon C. Ogg |

The Big Biotech Winners and Losers for 2013 (AMGN, BIIB, CELG, GILD, ALXN, ARIA, CBST, INCY, JAZZ, MDVN, ONXX, THRX, VPHM, VVUS)

ThinkstockBig biotech had a stellar 2012. In 2013, though, the large biotech companies may be dwarfed in performance by the…

Jon C. Ogg |

Big Biotech: Best of 2010, Outlook in 2011 (ILMN, ITMN, INCY, THRX, VPHM, DNDN, AMGN, GILD, CELG, HGSI, ACOR)

2010 is ending and 2011 is about to begin.  It has been a very interesting year for major biotech stocks,…

Top Analyst Upgrades and Downgrades: Brocade, Facebook, First Solar, Fitbit, ONEOK Partners, Sunrun and More
Jon C. Ogg |

Top Analyst Upgrades and Downgrades: Brocade, Facebook, First Solar, Fitbit, ONEOK Partners, Sunrun and More

The top analyst upgrades, downgrades and initiations seen on Thursday morning include Brocade Communications Systems, Facebook, First Solar, Fitbit, ONEOK…

Douglas A. McIntyre |

The Next Blockbuster Drugs: A $170 Billion Opportunity

Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line…

Top Gaining Stocks

Dell Technologies
DELL • Vol: 42,366,555
NetApp
NTAP • Vol: 15,911,807
ServiceNow
NOW • Vol: 68,243,561
IBM
IBM • Vol: 28,527,546
Hewlett Packard Enterprise
HPE • Vol: 86,996,387

Top Losing Stocks

Coterra Energy
CTRA • Vol: 73,319,495
Clorox
CLX • Vol: 4,744,001
ResMed
RMD • Vol: 3,526,686
Intel
INTC • Vol: 191,680,425
Skyworks Solutions
SWKS • Vol: 5,407,806